Hsiao Jane PH D 的 Form 4 申報
Opko Health, Inc.OPK，2024/1/8 申報
- 申報編號
- 0000950170-24-002743
- 申報時間
- 2024/1/8 09:10 ET
- 交易日
- 2024/1/4-1/5
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 1 筆非衍生性交易、2 筆衍生性交易。公開市場買進合計 $13.1 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Hsiao Jane PH DCIK 0001188834 | 董事、高階主管（副董事長、技術長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/1/5 | Common Stock | P買進取得 | +150,010 | $0.8726 | +$130,898.73 | 27,849,880 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The 5% Convertible Promissory Notes due 2025 were originally entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of such original notes, plus unpaid interest, into shares of the Issuer's (as defined below) common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. Pursuant to an amendment on February 10, 2023, the maturity date was extended to January 31, 2025, which amendment also reset the conversion price to the 10 day volume weighted average price immediately preceding the date of such amendment, plus a 25% conversion premium, or $1.66.
表 II 有 1 筆交易的價格引用這則附註。
- F4
The reporting person entered into a Convertible Note Purchase Agreement with OPKO Health, Inc. (the "Issuer") on January 4, 2024, pursuant to which the reporting person disposed of $5,000,000 aggregate principal amount of 5% Convertible Promissory Notes due 2025, and accrued and unpaid interest thereon, in exchange for $6,452,000 aggregate principal amount of the Issuer's 3.75% Convertible Senior Notes due 2029 in a private placement.
表 II 有 1 筆交易的價格引用這則附註。